EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
Share
Why It Matters
Scienture's sales jumped way up this quarter from new drugs selling well. When a company grows this fast but plans profit for 2027, watch if they keep growing or run out of money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.